Total for the last 12 months
number of access : ?
number of downloads : ?
ID 118973
Ueki, Yuya Tokushima University
Ikemitsu, Daiki Tokushima University
Azane, Shota Tokushima University
Kunikane, Yamato Tokushima University
Bando, Takanori Tokushima University
Matsuda, Noritake Tokushima University
Somatostatin receptor (SSTR)
Somatostatin receptor scintigraphy (SRS)
Neuroendocrine tumors (NETs)
Becquerel calibration factor (BCF)
Standardized uptake value (SUV)
Content Type
Journal Article
Purpose: Somatostatin receptor scintigraphy (SRS) using 111In-DTPA-DPhe1-octreotide (pentetreotide) has become an integral part of neuroendocrine neoplasm management. The lack of precise quantification is a disadvantage of SRS. This study aimed to adapt the standardized uptake value (SUV) to SRS, establish the SUV range for physiological uptake in the liver, kidney, and spleen, and elucidate the utility of combined visual and quantitative SRS assessment for staging and restaging of neuroendocrine tumors (NETs).
Materials and methods: This study included 21 patients with NETs who underwent 111In-pentetreotide SRS. The SUV of physiological and pathological uptake was calculated using bone single-photon emission computed tomography (SPECT) quantitative analysis software (GI-BONE). For visual analysis, the primary and metastatic lesions were scored visually on planar and SPECT images using a five-point scale. We assessed the relationships between the SUVs of the liver, kidney, and spleen in the dual phase, and among quantitative indices, visual score, and pathological lesions classification.
Results: Sixty-three NEN lesions were evaluated. The mean±standard deviation maximum SUVs (SUVmax) were liver: 4 h, 2.6±1.0; 24 h, 2.2±1.0; kidney: 4 h, 8.9±1.8; 24 h, 7.0±2.0; and spleen; 4 h, 11.3±4.5; 24 h, 11.5±7.6. Higher SUVmax was significantly associated with higher visual scores on dual-phase SPECT (4 h, p <0.001; 24 h, p <0.001) (4 h: scores 3 and 4, p <0.05; scores 3 and 5: p <0.01; scores 4 and 5: p <0.01; 24 h: scores 3 and 4, p=0.0748; scores 3 and 5: p <0.01; scores 4 and 5: p <0.01).
Conclusion: We adapted the SUV to SRS and established the range of SUV for physiological uptake in the liver, kidney, and spleen. Combined visual and quantitative assessment is useful for imaging individual lesions in greater detail, and may serve as a new tumor marker of SRS for staging and restaging of NETs.
Journal Title
Japanese Journal of Radiology
Japan Radiological Society|Springer Nature
Published Date
This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use (, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at:
DOI (Published Version)
URL ( Publisher's Version )
Medical Sciences
Advance Radiation Research, Education, and Management Center
University Hospital